ArQule Gets a New CEO

Woburn, MA-based ArQule, which is developing several compounds known as kinase inhibitors as potential cancer therapies, said today that Paolo Pucci, a Bayer senior vice president overseeing Bayer-Schering’s global oncology and  therapeutics business, will take over as the company’s new CEO. Pucci succeeds Stephen Hill, a nine-year veteran of the company who announced his approaching departure in January and left ArQule to become president and CEO of Brussels, Belgium-based Solvay Pharmaceuticals on April 1.

Wade Roush is a freelance science and technology journalist and the producer and host of the podcast Soonish. Follow @soonishpodcast

Trending on Xconomy